Neuren Pharmaceuticals Annual Report 2018

Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for debilitating neurodevelopmental disorders that are characterised by impaired connections and signalling between brain cells. Incorporated in New Zealand and based in Melbourne, Australia, Neuren is listed on the ASX under the code NEU. The Board of Directors is pleased to present the Annual Report of Neuren Pharmaceuticals Limited for the year ended 31 December 2018, authorised on 24 April 2019. For, and on behalf of, the Board Dr Richard Treagus Chairman Dr Trevor Scott Director 1 Why invest in Neuren? 2 Chairman’s Letter 3 Operating Review 14 Leadership Team 16 Corporate Governance 22 Directors’ Report 26 Consolidated Statement of Comprehensive Income 27 Consolidated Statement of Financial Position 28 Consolidated Statement of Changes in Equity 29 Consolidated Statement of Cash Flows 30 Notes to the Consolidated Financial Statements 46 Independent Auditor’s Report 49 Additional Information

RkJQdWJsaXNoZXIy MjE2NDg3